Article
A Preclinical Model of Obesity-Independent Metabolic Syndrome for Studying the Effects of Novel Antidiabetic Therapy Beyond Glycemic Control
2023-11-17
Abstract excerpt
Accumulating data from several large, placebo-controlled studies suggests that sodium-glucose transporter 2 (SGLT-2) inhibitors and glucagon-like peptide 1 receptor (GLP-1) receptor agonists offer therapeutic benefits in the management of cardiovascular diseases, regardless of the patient’s diabetic status. In addition to their effects on glucose excretion, SGLT2 inhibitors have a positive impact on systemic metab...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 495cbf21-241d-5d13-8d56-f666cf2bd329
- DOI
- 10.22541/au.170022092.29999283/v1
